Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification.
Identifieur interne : 004D33 ( PubMed/Checkpoint ); précédent : 004D32; suivant : 004D34Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification.
Auteurs : M R Luquin ; O. Scipioni ; J. Vaamonde ; O. Gershanik ; J A ObesoSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 1992.
English descriptors
- KwdEn :
- Aged, Apomorphine (diagnostic use), Chlorpromazine (administration & dosage), Chlorpromazine (adverse effects), Dopamine Agents (administration & dosage), Dopamine Agents (adverse effects), Dose-Response Relationship, Drug, Dyskinesia, Drug-Induced (classification), Dyskinesia, Drug-Induced (diagnosis), Dyskinesia, Drug-Induced (drug therapy), Electromyography (drug effects), Female, Humans, Levodopa (adverse effects), Levodopa (therapeutic use), Lisuride (diagnostic use), Male, Middle Aged, Neurologic Examination (drug effects), Parkinson Disease (classification), Parkinson Disease (diagnosis), Parkinson Disease (drug therapy), Parkinson Disease, Secondary (chemically induced), Parkinson Disease, Secondary (classification), Parkinson Disease, Secondary (diagnosis), Parkinson Disease, Secondary (drug therapy), Receptors, Dopamine (drug effects), Sulpiride (administration & dosage), Sulpiride (adverse effects).
- MESH :
- chemical , administration & dosage : Chlorpromazine, Dopamine Agents, Sulpiride.
- chemical , adverse effects : Chlorpromazine, Dopamine Agents, Levodopa, Sulpiride.
- chemical , diagnostic use : Apomorphine, Lisuride.
- chemically induced : Parkinson Disease, Secondary.
- classification : Dyskinesia, Drug-Induced, Parkinson Disease, Parkinson Disease, Secondary.
- diagnosis : Dyskinesia, Drug-Induced, Parkinson Disease, Parkinson Disease, Secondary.
- drug effects : Electromyography, Neurologic Examination, Receptors, Dopamine.
- drug therapy : Dyskinesia, Drug-Induced, Parkinson Disease, Parkinson Disease, Secondary.
- chemical , therapeutic use : Levodopa.
- Aged, Dose-Response Relationship, Drug, Female, Humans, Male, Middle Aged.
Abstract
Levodopa-induced dyskinesias (LID) in Parkinson's disease (PD) may be classified into three main categories: "On" dyskinesias, diphasic dyskinesias (DD), and "off" periods. The study of 168 parkinsonian patients showed that about half (n = 84) showed one pattern of LID only. A combination of two was present in 68, and 16 had the three presentation patterns. A fairly good correlation between type of dyskinesia and presentation pattern was established. Chorea, myoclonus, and dystonic movements occurred during the "on" period. Dystonic postures, particularly affecting the feet, were mainly present in the "off" period, but a few patients had a diphasic presentation. Repetitive stereotyped movements of the lower limbs always corresponded to DD. Acute pharmacological tests using dopamine agonists (subcutaneous apomorphine 3-8 mg; intravenous lisuride 0.1-0.15 mg) and dopamine antagonists (intravenous sulpiride 200-400 mg and intravenous chlorpromazine 25 mg) were performed in 40 patients. Dopamine agonists enhanced "on" dyskinesias and markedly reduced or abolished "off" period dystonia and DD. Dopamine antagonists reduced all types of LID but usually aggravated parkinsonism. These clinical and pharmacological results indicate that LID in PD are a heterogeneous phenomenon difficult to explain on the basis of a single pathophysiological mechanism.
DOI: 10.1002/mds.870070204
PubMed: 1350058
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:1350058Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification.</title><author><name sortKey="Luquin, M R" sort="Luquin, M R" uniqKey="Luquin M" first="M R" last="Luquin">M R Luquin</name><affiliation><nlm:affiliation>Department of Neurology, Clinica Universitaria, University of Navarra, Pamplona-Spain.</nlm:affiliation><wicri:noCountry code="subField">Pamplona-Spain</wicri:noCountry></affiliation></author><author><name sortKey="Scipioni, O" sort="Scipioni, O" uniqKey="Scipioni O" first="O" last="Scipioni">O. Scipioni</name></author><author><name sortKey="Vaamonde, J" sort="Vaamonde, J" uniqKey="Vaamonde J" first="J" last="Vaamonde">J. Vaamonde</name></author><author><name sortKey="Gershanik, O" sort="Gershanik, O" uniqKey="Gershanik O" first="O" last="Gershanik">O. Gershanik</name></author><author><name sortKey="Obeso, J A" sort="Obeso, J A" uniqKey="Obeso J" first="J A" last="Obeso">J A Obeso</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1992">1992</date><idno type="RBID">pubmed:1350058</idno><idno type="pmid">1350058</idno><idno type="doi">10.1002/mds.870070204</idno><idno type="wicri:Area/PubMed/Corpus">004D73</idno><idno type="wicri:Area/PubMed/Curation">004D73</idno><idno type="wicri:Area/PubMed/Checkpoint">004D33</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification.</title><author><name sortKey="Luquin, M R" sort="Luquin, M R" uniqKey="Luquin M" first="M R" last="Luquin">M R Luquin</name><affiliation><nlm:affiliation>Department of Neurology, Clinica Universitaria, University of Navarra, Pamplona-Spain.</nlm:affiliation><wicri:noCountry code="subField">Pamplona-Spain</wicri:noCountry></affiliation></author><author><name sortKey="Scipioni, O" sort="Scipioni, O" uniqKey="Scipioni O" first="O" last="Scipioni">O. Scipioni</name></author><author><name sortKey="Vaamonde, J" sort="Vaamonde, J" uniqKey="Vaamonde J" first="J" last="Vaamonde">J. Vaamonde</name></author><author><name sortKey="Gershanik, O" sort="Gershanik, O" uniqKey="Gershanik O" first="O" last="Gershanik">O. Gershanik</name></author><author><name sortKey="Obeso, J A" sort="Obeso, J A" uniqKey="Obeso J" first="J A" last="Obeso">J A Obeso</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="1992" type="published">1992</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Apomorphine (diagnostic use)</term><term>Chlorpromazine (administration & dosage)</term><term>Chlorpromazine (adverse effects)</term><term>Dopamine Agents (administration & dosage)</term><term>Dopamine Agents (adverse effects)</term><term>Dose-Response Relationship, Drug</term><term>Dyskinesia, Drug-Induced (classification)</term><term>Dyskinesia, Drug-Induced (diagnosis)</term><term>Dyskinesia, Drug-Induced (drug therapy)</term><term>Electromyography (drug effects)</term><term>Female</term><term>Humans</term><term>Levodopa (adverse effects)</term><term>Levodopa (therapeutic use)</term><term>Lisuride (diagnostic use)</term><term>Male</term><term>Middle Aged</term><term>Neurologic Examination (drug effects)</term><term>Parkinson Disease (classification)</term><term>Parkinson Disease (diagnosis)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease, Secondary (chemically induced)</term><term>Parkinson Disease, Secondary (classification)</term><term>Parkinson Disease, Secondary (diagnosis)</term><term>Parkinson Disease, Secondary (drug therapy)</term><term>Receptors, Dopamine (drug effects)</term><term>Sulpiride (administration & dosage)</term><term>Sulpiride (adverse effects)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Chlorpromazine</term><term>Dopamine Agents</term><term>Sulpiride</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Chlorpromazine</term><term>Dopamine Agents</term><term>Levodopa</term><term>Sulpiride</term></keywords><keywords scheme="MESH" type="chemical" qualifier="diagnostic use" xml:lang="en"><term>Apomorphine</term><term>Lisuride</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Parkinson Disease, Secondary</term></keywords><keywords scheme="MESH" qualifier="classification" xml:lang="en"><term>Dyskinesia, Drug-Induced</term><term>Parkinson Disease</term><term>Parkinson Disease, Secondary</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Dyskinesia, Drug-Induced</term><term>Parkinson Disease</term><term>Parkinson Disease, Secondary</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Electromyography</term><term>Neurologic Examination</term><term>Receptors, Dopamine</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Dyskinesia, Drug-Induced</term><term>Parkinson Disease</term><term>Parkinson Disease, Secondary</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Levodopa</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Dose-Response Relationship, Drug</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Levodopa-induced dyskinesias (LID) in Parkinson's disease (PD) may be classified into three main categories: "On" dyskinesias, diphasic dyskinesias (DD), and "off" periods. The study of 168 parkinsonian patients showed that about half (n = 84) showed one pattern of LID only. A combination of two was present in 68, and 16 had the three presentation patterns. A fairly good correlation between type of dyskinesia and presentation pattern was established. Chorea, myoclonus, and dystonic movements occurred during the "on" period. Dystonic postures, particularly affecting the feet, were mainly present in the "off" period, but a few patients had a diphasic presentation. Repetitive stereotyped movements of the lower limbs always corresponded to DD. Acute pharmacological tests using dopamine agonists (subcutaneous apomorphine 3-8 mg; intravenous lisuride 0.1-0.15 mg) and dopamine antagonists (intravenous sulpiride 200-400 mg and intravenous chlorpromazine 25 mg) were performed in 40 patients. Dopamine agonists enhanced "on" dyskinesias and markedly reduced or abolished "off" period dystonia and DD. Dopamine antagonists reduced all types of LID but usually aggravated parkinsonism. These clinical and pharmacological results indicate that LID in PD are a heterogeneous phenomenon difficult to explain on the basis of a single pathophysiological mechanism.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">1350058</PMID><DateCreated><Year>1992</Year><Month>06</Month><Day>12</Day></DateCreated><DateCompleted><Year>1992</Year><Month>06</Month><Day>12</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN><JournalIssue CitedMedium="Print"><Volume>7</Volume><Issue>2</Issue><PubDate><Year>1992</Year></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification.</ArticleTitle><Pagination><MedlinePgn>117-24</MedlinePgn></Pagination><Abstract><AbstractText>Levodopa-induced dyskinesias (LID) in Parkinson's disease (PD) may be classified into three main categories: "On" dyskinesias, diphasic dyskinesias (DD), and "off" periods. The study of 168 parkinsonian patients showed that about half (n = 84) showed one pattern of LID only. A combination of two was present in 68, and 16 had the three presentation patterns. A fairly good correlation between type of dyskinesia and presentation pattern was established. Chorea, myoclonus, and dystonic movements occurred during the "on" period. Dystonic postures, particularly affecting the feet, were mainly present in the "off" period, but a few patients had a diphasic presentation. Repetitive stereotyped movements of the lower limbs always corresponded to DD. Acute pharmacological tests using dopamine agonists (subcutaneous apomorphine 3-8 mg; intravenous lisuride 0.1-0.15 mg) and dopamine antagonists (intravenous sulpiride 200-400 mg and intravenous chlorpromazine 25 mg) were performed in 40 patients. Dopamine agonists enhanced "on" dyskinesias and markedly reduced or abolished "off" period dystonia and DD. Dopamine antagonists reduced all types of LID but usually aggravated parkinsonism. These clinical and pharmacological results indicate that LID in PD are a heterogeneous phenomenon difficult to explain on the basis of a single pathophysiological mechanism.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Luquin</LastName><ForeName>M R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Department of Neurology, Clinica Universitaria, University of Navarra, Pamplona-Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scipioni</LastName><ForeName>O</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Vaamonde</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Gershanik</LastName><ForeName>O</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Obeso</LastName><ForeName>J A</ForeName><Initials>JA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>UNITED STATES</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015259">Dopamine Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011954">Receptors, Dopamine</NameOfSubstance></Chemical><Chemical><RegistryNumber>46627O600J</RegistryNumber><NameOfSubstance UI="D007980">Levodopa</NameOfSubstance></Chemical><Chemical><RegistryNumber>7MNE9M8287</RegistryNumber><NameOfSubstance UI="D013469">Sulpiride</NameOfSubstance></Chemical><Chemical><RegistryNumber>E0QN3D755O</RegistryNumber><NameOfSubstance UI="D008090">Lisuride</NameOfSubstance></Chemical><Chemical><RegistryNumber>N21FAR7B4S</RegistryNumber><NameOfSubstance UI="D001058">Apomorphine</NameOfSubstance></Chemical><Chemical><RegistryNumber>U42B7VYA4P</RegistryNumber><NameOfSubstance UI="D002746">Chlorpromazine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001058">Apomorphine</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000176">diagnostic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D002746">Chlorpromazine</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration & dosage</QualifierName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015259">Dopamine Agents</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration & dosage</QualifierName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004409">Dyskinesia, Drug-Induced</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000145">classification</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004576">Electromyography</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007980">Levodopa</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008090">Lisuride</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000176">diagnostic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009460">Neurologic Examination</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000145">classification</QualifierName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010302">Parkinson Disease, Secondary</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName><QualifierName MajorTopicYN="N" UI="Q000145">classification</QualifierName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011954">Receptors, Dopamine</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D013469">Sulpiride</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration & dosage</QualifierName><QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1992</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1992</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1992</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">1350058</ArticleId><ArticleId IdType="doi">10.1002/mds.870070204</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list></list><tree><noCountry><name sortKey="Gershanik, O" sort="Gershanik, O" uniqKey="Gershanik O" first="O" last="Gershanik">O. Gershanik</name><name sortKey="Luquin, M R" sort="Luquin, M R" uniqKey="Luquin M" first="M R" last="Luquin">M R Luquin</name><name sortKey="Obeso, J A" sort="Obeso, J A" uniqKey="Obeso J" first="J A" last="Obeso">J A Obeso</name><name sortKey="Scipioni, O" sort="Scipioni, O" uniqKey="Scipioni O" first="O" last="Scipioni">O. Scipioni</name><name sortKey="Vaamonde, J" sort="Vaamonde, J" uniqKey="Vaamonde J" first="J" last="Vaamonde">J. Vaamonde</name></noCountry></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004D33 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 004D33 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:1350058
|texte= Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:1350058" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |